

2022

Public engagement highlights

Annual overview of the involvement of patients and healthcare professionals (HCP) in the work of EMA

In 2022, as COVID-19 restrictions eased, EMA met patient and HCP representatives face-to-face for the first time since 2019. Priorities to enhance the collection and use of patient experience data for medicines development and regulation were agreed with stakeholders. Experience on [patients' early dialogue with CHMP](#) was analysed and will continue, expanding to HCP. A [published study](#) highlighted the impact of patient contribution to scientific advice procedures. Patient and HCP representatives joined the Medicines Shortages Steering Group ([MSSG](#)). The end of the year saw the start of the next mandate of the [PCWP/HCPWP](#) and the election of new co-chairs.



Stakeholder involvement in medicine*

Patient contribution to EMA's work

Patient membership numbers	57
EMA Management Board	2
Scientific committees	12
Patients' and Consumers' Working Party	43
Active patient experts	80
PCO eligible organisations	42

HCP contribution to EMA's work

HCP membership numbers	57
EMA Management Board	2
Scientific committees	12
Patients' and Consumers' Working Party	42
Active HCP experts	140
HCP eligible organisations	39

* In 2022, the Public and Stakeholder engagement department changed its reporting methodology to include the number of eligible organisations and corresponding experts in the database.

Key events

Multistakeholder workshop on EMA's Extended Mandate

Patients and HCP representatives joined this event informing all stakeholders of the regulation reinforcing EMA's role in public health emergencies, monitoring and mitigating shortages and coordinating expert panels on high-risk medical devices and in vitro diagnostics.

[View event summary](#)

Multistakeholder event on patient experience data

This workshop gathered input from patients, consumers, healthcare professionals, academia, regulators, health technology assessment bodies and industry on what constitutes 'Patient Experience Data' and how to best collect and use this data to ensure the patient perspective is systematically captured in medicine development and evaluation.

[View event summary](#)

Working party meetings

March

ACT EU, Big Data, electronic product information, EMA's extended mandate, Advanced Therapy Medicinal Products (ATMPs)

[Access meeting documents](#)

June

New mandate and introduction to new members, Clinical Trials, COVID-19 updates, Big Data, creation of joint drafting group on the ICH E6 guidance on Good Clinical Practice

[Access meeting documents](#)

September

Update on COVID-19, Big Data, use of EMA communications, election on new co-chairs


[Access meeting documents](#)

November

Patient Experience Data, medicine shortages, HTA activities, antimicrobial resistance

[Access meeting documents](#)

Queries by stakeholder



Total number queries: **2374**

Overall satisfaction **68%**

Common topics

COVID-19 | Availability | Paediatrics | Comirnaty | Boosters | Adverse drug reactions | Valneva